(Q41419015)

30 September 2017

1 reference

title

Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents (English)

1 reference

30 September 2017

1 reference

J Lokich

1

1 reference

PubMed ID

9093703

30 September 2017

N Anderson

series ordinal

2

1 reference

30 September 2017

1 January 1997

1 reference

30 September 2017

1 reference

30 September 2017

8

1 reference

30 September 2017

15-25

1 reference

30 September 2017

1

1 reference

Continuous infusion chemotherapy: a critical review

30 September 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Systemic infusion versus bolus chemotherapy with 5-fluorouracil in measurable metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I study of protracted venous infusion of 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Studies of hydroxyurea administered by continuous infusion: toxicity, pharmacokinetics, and cell synchronization

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Long-term intravenous hydroxyurea infusions in patients with advanced cancer. A phase I trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I clinical investigation of fludarabine phosphate by a loading-dose and continuous-infusion schedule

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I study of cyclophosphamide (NSC 26271) by 72-hour continuous intravenous infusion.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I clinical and pharmacokinetic study of cyclophosphamide administered by five-day continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase-I study of continuous infusion cyclophosphamide for protracted durations: a preliminary report

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

High-dose ifosfamide with mesna uroprotection: a phase I study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Ifosfamide treatment as a 10-day continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase I study of thiotepa administered by short-term and protracted continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Infusional carboplatin. Phase I studies of 5-day and 14-day infusions

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Continuous infusion carboplatin on a 21-day schedule: a phase I and pharmacokinetic study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase II clinical trial of carboplatin infusion in high-risk acute nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase I trial of 14-day continuous intravenous infusion mitoxantrone

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

A phase I trial of continuous infusion VP16-213 (etoposide).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Taxol administered as a 120 hour infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: a phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Evaluating cancer chemotherapy by infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008243806415

7 January 2021

Identifiers

DOI

10.1023/A:1008243806415

1 reference

30 September 2017

1 reference

PubMed ID

9093703